Doxycycline Patent Expiration
Doxycycline is Used for treating inflammatory lesions of rosacea. It was first introduced by Pfizer Laboratories Div Pfizer Inc
Doxycycline Patents
Given below is the list of patents protecting Doxycycline, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Oracea | US7749532 | Once daily formulations of tetracyclines | Dec 19, 2027 | Galderma Labs Lp |
| Oracea | US8206740 | Once daily formulations of tetracyclines |
Dec 24, 2025
(Expired) | Galderma Labs Lp |
| Oracea | US8394405 | Once daily formulations of tetracyclines |
Apr 07, 2024
(Expired) | Galderma Labs Lp |
| Oracea | US8394406 | Once daily formulations of tetracyclines |
Apr 07, 2024
(Expired) | Galderma Labs Lp |
| Oracea | US8470364 | Once daily formulations of tetracyclines |
Apr 07, 2024
(Expired) | Galderma Labs Lp |
| Oracea | US8709478 | Once daily formulations of tetracyclines |
Apr 07, 2024
(Expired) | Galderma Labs Lp |
| Oracea | US10058564 | Methods of treating acne |
Apr 05, 2022
(Expired) | Galderma Labs Lp |
| Oracea | US7211267 | Methods of treating acne |
Apr 05, 2022
(Expired) | Galderma Labs Lp |
| Oracea | US7232572 | Methods of treating rosacea |
Apr 05, 2022
(Expired) | Galderma Labs Lp |
| Oracea | US8603506 | Methods of treating acne |
Apr 05, 2022
(Expired) | Galderma Labs Lp |
| Oracea | US9241946 | Methods of treating acne |
Apr 05, 2022
(Expired) | Galderma Labs Lp |
| Oracea | US5789395 | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
Aug 30, 2016
(Expired) | Galderma Labs Lp |
| Oracea | US5919775 | Method for inhibiting expression of inducible nitric oxide synthase with tetracycline |
Aug 30, 2016
(Expired) | Galderma Labs Lp |
Doxycycline's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Doxycycline:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
